Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Abstract Text:

Meena Rafiq,Sarah E Flanagan,Ann-Marie Patch,Beverley M Shields,Sian Ellard,Andrew T Hattersley, ,Meena Rafiq,Sarah E Flanagan,Ann-Marie Patch,Beverley M Shields,Sian Ellard,Andrew T Hattersley, ,

OBJECTIVE: Neonatal diabetes can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K(+) channel. Transfer from insulin to oral sulfonylureas in patients with neonatal diabetes due to Kir6.2 mutations is well described, but less is known about changing therapy in patients with SUR1 mutations. We aimed to describe the response to sulfonylurea therapy in patients with SUR1 mutations and to compare it with Kir6.2 mutations. RESEARCH DESIGN AND METHODS: We followed 27 patients with SUR1 mutations for at least 2 months after attempted transfer to sulfonylureas. Information was collected on clinical features, treatment before and after transfer, and the transfer protocol used. We compared successful and unsuccessful transfer patients, glycemic control before and after transfer, and treatment requirements in patients with SUR1 and Kir6.2 mutations. RESULTS: Twenty-three patients (85%) successfully transferred onto sulfonylureas without significant side effects or increased hypoglycemia and did not need insulin injections. In these patients, median A1C fell from 7.2% (interquartile range 6.6-8.2%) on insulin to 5.5% (5.3-6.2%) on sulfonylureas (P = 0.01). When compared with Kir6.2 patients, SUR1 patients needed lower doses of both insulin before transfer (0.4 vs. 0.7 units x kg(-1) x day(-1); P = 0.002) and sulfonylureas after transfer (0.26 vs. 0.45 mg x kg(-1) x day(-1); P = 0.005). CONCLUSIONS: Oral sulfonylurea therapy is safe and effective in the short term in most patients with diabetes due to SUR1 mutations and may successfully replace treatment with insulin injections. A different treatment protocol needs to be developed for this group because they require lower doses of sulfonylureas than required by Kir6.2 patients.

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Publishing Authors By Initials

M Rafiq,SE Flanagan,AM Patch,BM Shields,S Ellard,AT Hattersley, ,M Rafiq,SE Flanagan,AM Patch,BM Shields,S Ellard,AT Hattersley, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Diabetes care

VOLUME: 31

Page Numbers: 204-9

Journal Abbreviation: Diabetes Care

ISSN: 1935-5548

DAY: 19

MONTH: 11

YEAR: 2007

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7805975

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.

AFFILIATION: Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, UK.

Country: United States

AGENCY: United Kingdom Wellcome T

GRANT:

ACRONYM:

MEDLINETA: Diabetes Care

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 SUR1 mutations Related Publications

• 'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing.
• A severe clinical phenotype results from the co-inheritance of type 2 susceptibility genes and a hepatocyte nuclear factor-1alpha mutation.
• Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young.
• Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers.
• Blood transfusions and the Rh factor.
• Can molecular genetics help in the clinic?
• Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation.
• Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes.
• Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta mutations.
• Diagnosis of maturity-onset diabetes of the young in the pediatric diabetes clinic.
• Different genes, different diabetes: lessons from maturity-onset diabetes of the young.
• Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
• Genetics and type 2 diabetes in youth.
• Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics.
• Identifying hepatic nuclear factor 1alpha mutations in children and young adults with a clinical diagnosis of type 1 diabetes.
• Impaired maximum microvascular hyperaemia in patients with MODY 3 (hepatocyte nuclear factor-1alpha gene mutations).
• Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-1alpha gene mutation carriers.
• Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes.
• Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity.
• Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization.
• Mutations in hepatocyte nuclear factor 1beta are not a common cause of maturity-onset diabetes of the young in the U.K.
• Mutations in the glucokinase gene of the fetus result in reduced placental weight.
• No evidence for linkage at candidate type 2 diabetes susceptibility loci on chromosomes 12 and 20 in United Kingdom Caucasians.
• Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.
• Proposed mechanism for a novel insertion/deletion frameshift mutation (I414G415ATCG-->CCA) in the hepatocyte nuclear factor 1 alpha (HNF-1 alpha) gene which causes maturity-onset diabetes of the young (MODY).
• Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
• Serum amino acids in patients with mutations in the hepatocyte nuclear factor-1 alpha gene.
• The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1alpha mutations is a feature of all patients with diabetes and is associated with glucosuria.
• beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors.
• beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations.